Heart rehab after immunotherapy side effects study
Part of Heart & circulation, Immune system & allergy clinical trials.
This study follows people who had a heart-related side effect from immunotherapy and are now ready for rehab. It aims to better understand recovery and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age must be between 18 and 80 years old.
- You must have a confirmed cancer diagnosis (by biopsy or lab test).
- You must have had a heart or blood vessel side effect caused by immunotherapy (called ICIACI).
- Your treatment team must have said you have recovered from that side effect and can start rehabilitation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a rehabilitation program called ICIAM for people whose heart muscle became inflamed (myocarditis) after immunotherapy for cancer. It combines Western rehab with Traditional Chinese Medicine to help you recover better.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
Hear when a new Immune Checkpoint Inhibitor-Related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.